Your browser is no longer supported. Please, upgrade your browser.
Settings
EWTX [NASD]
Edgewise Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own13.30% Shs Outstand49.26M Perf Week5.14%
Market Cap823.10M Forward P/E- EPS next Y-1.18 Insider Trans49.19% Shs Float48.61M Perf Month20.15%
Income-24.30M PEG- EPS next Q-0.22 Inst Own99.45% Short Float4.32% Perf Quarter-24.05%
Sales- P/S- EPS this Y-76.40% Inst Trans5.56% Short Ratio15.71 Perf Half Y-39.37%
Book/sh6.02 P/B3.02 EPS next Y-22.90% ROA- Target Price- Perf Year-
Cash/sh6.61 P/C2.75 EPS next 5Y- ROE- 52W Range13.60 - 40.49 Perf YTD-39.37%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.08% Beta-
Dividend %- Quick Ratio45.00 Sales past 5Y- Gross Margin- 52W Low33.75% ATR1.76
Employees26 Current Ratio45.00 Sales Q/Q- Oper. Margin- RSI (14)55.31 Volatility13.20% 10.21%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.06 Prev Close18.55
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume133.73K Price18.19
Recom- SMA209.92% SMA504.56% SMA200-21.57% Volume141,339 Change-1.94%
Sep-25-21 09:57AM  
Sep-14-21 09:00AM  
Aug-16-21 09:00AM  
Aug-09-21 09:00AM  
Aug-04-21 09:00AM  
Jul-28-21 10:45AM  
Jun-27-21 05:12AM  
Jun-22-21 09:00AM  
Jun-01-21 09:00AM  
May-13-21 04:01PM  
May-04-21 09:00AM  
Apr-27-21 09:00AM  
Apr-16-21 07:31PM  
Mar-30-21 04:01PM  
08:06AM  
Mar-25-21 10:23PM  
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EPossible Member of 10% GroupMar 30Buy16.00625,00010,000,0003,933,137Mar 30 03:42 PM
ROOT JONATHAN DDirectorMar 30Buy16.0015,625250,00015,625Mar 31 07:12 PM
Thompson Peter A.DirectorMar 30Buy16.00359,3755,750,00013,359,456Mar 31 07:11 PM
ORBIMED ADVISORS LLCDirectorMar 30Buy16.00359,3755,750,00013,359,456Mar 31 07:10 PM
Novo Holdings A/S10% OwnerMar 30Buy16.00625,00010,000,0005,587,207Mar 31 04:36 PM